

ONLINE FILING

Date: 10th May 2021

The Secretary National Stock Exchange of India Ltd. Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai-400 051	The Secretary, BSE Ltd Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400 001
---	---

Sub: Outcome of Board Meeting held on May 10, 2021

Dear Sir/Mam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors at its meeting held today, inter alia, considered and approved the following:

1. Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended March 31, 2021;
2. Appointment of Mr. Sunil Tandon as an Additional Director (Independent) on the Board of the Company with effect from May 10, 2021 to hold office as an Independent Director for a period of 5 years, subject to the approval of Shareholders in the ensuing Annual General Meeting. He is not debarred from appointment pursuant to any order of SEBI or any other authority.
3. The Board of Directors has recommended the appointment of M/s TR Chadha & Co. LLP, (FRN:006711N/N500028) as a statutory auditor of the Company for a period of five years from the conclusion of 17th Annual General Meeting ("AGM") till the conclusion of 22nd AGM, subject to approval of the Members of the Company.
4. The Board has taken a cognizance on the construction of the new Tower for expansion of upto 160 beds. The construction has commenced and is in full swing and the same is expected to operationalize by September 2021.

A copy of the Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended March 31, 2021 along with statements of Assets & Liabilities, Auditors'



Artemis Hospital (A unit of Artemis Medicare Services Ltd.)

Sector 51, Gurugram - 122001, Haryana, India. Ph.: +91-124-4511 111 | Fax: +91-124-4588 899
Emergency & Trauma: +91-124-4588 888

Registered Office: Plot No. 14, Sector 20, Dwarka, New Delhi - 110075 | Corporate Office: Artemis Hospital, Sector 51, Gurugram - 122001, Haryana, India
CIN: L85110DL2004PLC126414 | GST: 06AAFCA0130M1Z1(HR), 07AAFCA0130M1ZZ(DEL) | TAN: DELA16048E | PAN: AAFCA0130M | Email: info@artemishospitals.com




Report and declaration on Audit Reports with unmodified opinion are enclosed herewith for your records.

The detailed disclosure as per Regulation 30 of Listing Regulations, 2015 is given in the enclosed Annexure I.

The meeting of the Board of Directors commenced at 3:00 PM and concluded at 5.36 PM.
Submitted for your information & records.

Thanking you,
Yours Faithfully,

For Artemis Medicare Services Limited



Shilpa Budhia
(Company Secretary & Compliance Officer)

Annexure I

Appointment of Mr. Sunil Tandon as an Additional Director (Independent) on the Board of the Company.

Sr. No.	Detail of event reported	Information of Event
1.	Reason for disclosure	Appointment of Mr. Sunil Tandon as an Additional Director (Independent) to hold office as an Independent Director
2.	Date of appointment	May 10, 2021
3.	Term of appointment	For a period of 5 years with effect from May 10, 2021 to hold the office upto May 09, 2026, subject to the shareholders of the Company.
4.	Brief profile	Provided below
5.	Disclosure of relationship between Director	Mr. Sunil Tandon is not related to any Director of the Company and none of the Director on the Board has any concerned or interest in the said appointment

Brief Profile

Mr. Sunil Tandon is a Mechanical Engineer from Delhi College of Engineering (1975 batch) and an MBA with top honours and a gold medal from FMS (1977 batch), University of Delhi. He started his career with Engineers India Ltd. a premier Engineering design consultancy, where he had the opportunity of working with International Engineering design companies like Toyo, Snam Progetti etc.

Thereafter, Mr. Sunil Tandon had changed over to commercial aspects of business, including Purchase & Project exports at Ballarpur Industries Ltd, followed by a stint as Executive Asstt. to Vice Chairman at Modi Alkalies & Chemicals with exposure to diverse functions.

Thereafter Mr. Sunil Tandon worked at Apollo Tyres, heading the Purchase & Export functions. This was followed by a migration to Apollo International, a part of Apollo Tyres group, formed to diversify across businesses & geographies.

Later, he started an entrepreneurial venture, engaged in export of Industrial & Agri tyres,

Shilpa Bhalerao

Auditor's Profile

M/s. TR Chadha & Co LLP having one of its office at B-30, Connaught Place, Kuthiala Building, New Delhi – 110 001 is amongst the top ten Audit Firms in India with presence from over 74 years. They have been one of India's prominent Chartered accountancy firms providing wide array financial and advisory services to numerous MNCs as well as reputed companies in India and across the globe, the diverse team consists of 19 partners and over 600 employees with over 150 Chartered Accountants and other domain experts. They are spread across 10 different locations providing with a geographical advantage.

Shilpa Bhandari

Independent Auditors' Report on the Consolidated Annual Financial Results of the Company Pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

INDEPENDENT AUDITORS' REPORT

TO THE BOARD OF DIRECTORS OF ARTEMIS MEDICARE SERVICES LIMITED

Report on the audit of the Consolidated Annual Financial Results

Opinion

We have audited the accompanying consolidated annual financial results of **Artemis Medicare Services Limited** (hereinafter referred to as the "Holding Company") and its subsidiary (Holding Company and its subsidiary together referred to as "the Group") for the year ended 31st March, 2021 attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid consolidated annual financial results:

- a. includes the annual financial results of the following entities :
Holding Company
Artemis Medicare Services Limited

Subsidiary
Artemis Cardiac Care Private Limited
- b. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- c. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of consolidated net profit and other comprehensive income and other financial information of the Group for the year ended 31st March, 2021.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results* section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the consolidated financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion on the consolidated annual financial results.



Other offices

505, 5th Floor, Tower B, World Trade Tower
Sector 16, Noida, 201301
T: +91-120-4814400

4/18, Asaf Ali Road,
New Delhi-110002
T: +91-11-23274888/77410

B-XIX-220, Rani Jhansi Road, Anandpur Mandi
Ludhiana – 121001
T: +91-161-2774527 • F: +91-161-2771618

Management's and Board of Directors' Responsibilities for the Consolidated Annual Financial Results

These consolidated annual financial results have been prepared on the basis of the consolidated Ind AS annual financial statements. The Holding Company's Management and the Board of Directors are responsible for the preparation and presentation of these consolidated annual financial results that give a true and fair view of the consolidated net profit and other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act; for safeguarding of the assets of each company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated annual financial results by the Management and the Directors of the Holding Company, as aforesaid.

In preparing the consolidated annual financial results, the respective Management and the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of each company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective management/Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of each company.

Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to consolidated Ind AS financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the consolidated annual financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.



- Evaluate the overall presentation, structure and content of the consolidated annual financial results, including the disclosures, and whether the consolidated annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group to express an opinion on the consolidated annual financial results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatement in the consolidated annual financial results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the consolidated annual financial results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatement in the consolidated annual financial results.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated annual financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular No CIR/CFD/CMD1/44/2019 dated 29th March, 2019 issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

Other Matter

The consolidated annual financial results include the results for the quarter ended 31st March, 2021 being the balancing figure between the audited figures in respect of the full financial year and the published audited year to date figures up to the third quarter of the current financial year. (Refer Note 4)

Our opinion is not modified in respect of this matter.

For SCV & CO. LLP
Chartered Accountants
Firm's Registration Number : 000235N/N500089




(RAJIV PURI)
PARTNER
MEMBERSHIP No. 084318
UDIN : 21084318AAAABJ4616

PLACE: NEW DELHI
DATED: MAY 10, 2021

ARTEMIS MEDICARE SERVICES LIMITED

Plot No.14, Sector 20, Dwarka, South West Delhi, Delhi- 110075

Ph.: +91-124-4511111; Fax: +91-124-4588899; Email: info@artemishospitals.com; Website: www.artemishospitals.com

CIN: L85110DL2004PLC126414

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2021

(₹ in Lacs)

S No.	Particulars	Quarter ended			Year ended	
		31-Mar-21	31-Dec-20	31-Mar-20	31-Mar-21	31-Mar-20
		(Audited) (Refer Note 4)	(Unaudited)	(Audited) (Refer Note 4)	(Audited)	(Audited)
1.	Income					
	(a) Revenue from Operations	12,915.89	12,418.69	13,847.09	40,840.34	56,501.79
	(b) Other Income	139.62	68.47	205.40	353.83	459.64
	Total Income	13,055.51	12,487.16	14,052.49	41,194.17	56,961.43
2.	Expenses					
	(a) Purchases of Pharmacy drugs & Medical consumables	3,581.39	3,716.54	3,689.25	11,488.70	14,123.78
	(b) Purchases of Stock in Trade	6.63	-	35.37	29.71	149.00
	(c) Changes in Inventories of Pharmacy drugs, Medical consumables & Stock in Trade	20.02	(113.42)	(280.29)	127.19	(383.69)
	(d) Employee Benefits Expense	2,188.82	2,186.73	2,643.91	8,399.01	10,342.49
	(e) Finance Costs	258.78	307.45	295.83	1,292.53	1,279.80
	(f) Depreciation and Amortization Expense	510.55	534.36	572.93	2,151.38	2,263.05
	(g) Other Expenses	5,095.60	5,023.24	6,463.40	17,275.92	26,124.09
	Total Expenses	11,661.79	11,654.90	13,420.40	40,764.44	53,898.52
3.	Profit before exceptional items and tax (1-2)	1,393.72	832.26	632.09	429.73	3,062.91
4.	Exceptional Items (Refer Note 8)	323.29	-	-	323.29	-
5.	Profit before tax (3+4)	1,717.01	832.26	632.09	753.02	3,062.91
6.	Tax Expense:					
	(a) Current Tax	670.51	-	281.70	670.51	1,139.63
	(b) Earlier Year Tax	94.14	-	(14.16)	94.14	(395.73)
	(c) Deferred Tax Charge / (Credit)	(312.80)	307.03	(57.73)	(627.63)	373.00
	Total Tax Expense	451.85	307.03	209.81	137.02	1,116.90
7.	Profit after tax for the period (5-6)	1,265.16	525.23	422.28	616.00	1,946.01
8.	Other Comprehensive Income					
	Items that will not be reclassified to profit or loss					
	(a) Remeasurement of defined employee benefit plans	17.94	(2.78)	(26.27)	9.62	(49.46)
	(b) Deferred Tax adjustment on revaluation	10.16	10.17	7.63	40.66	30.50
	(c) Income Tax relating to items that will not be reclassified to profit or loss	(6.21)	0.97	9.18	(3.30)	17.28
	Net other comprehensive income not to be reclassified to profit or loss in subsequent periods:	21.89	8.36	(9.46)	46.98	(1.68)
9.	Total comprehensive income for the period (7+8)	1,287.05	533.59	412.82	662.98	1,944.33
10.	Profit/(Loss) for the period attributable to :					
	Shareholders of the Company	1,269.97	533.72	431.43	648.58	1,979.26
	Non-Controlling Interest	(4.81)	(8.49)	(9.15)	(32.58)	(33.25)
11.	Total Comprehensive Income / (Loss) for the period attributable to :					
	Shareholders of the Company	1,291.63	542.08	421.97	695.33	1,977.58
	Non-Controlling Interest	(4.58)	(8.49)	(9.15)	(32.35)	(33.25)
12.	Paid up Equity Share Capital (Face value Rs. 10/- each)	1,323.77	1,323.77	1,323.77	1,323.77	1,323.77
13.	Other Equity Excluding Revaluation Reserves	-	-	-	24,056.65	23,401.98
14.	Earning per Equity Share (Face value Rs. 10/- each)					
	(a) Basic	9.59*	4.03*	3.26*	4.90	14.95
	(b) Diluted	9.59*	4.03*	3.26*	4.90	14.95

* Not annualised



Onkar Kumar

Notes:-

- The above consolidated audited financial results for the quarter and year ended March 31, 2021 have been reviewed by the Audit Committee and subsequently approved by the Board of Directors of the Company at their respective meetings held on May 10, 2021. The statutory auditors have expressed unmodified opinion on the aforesaid results.
- The consolidated audited financial results includes the results of the Company and one subsidiary. The Company together with its subsidiary is herein referred to as the Group.
- The above consolidated financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015, as amended (Ind AS), as prescribed under Section 133 of the Companies Act 2013, and the other recognised accounting practices and policies to the extent applicable.
- The results for the quarter ended March 31, 2021 and March 31, 2020, are the balancing figures between audited figures in respect of full financial year ended March 31, 2021 and March 31, 2020 respectively and published and unaudited respectively year to date figures up to the third quarter of the respective financial year then ended.
- The Parliament of India has approved the Code of Social Security, 2020 (the Code) which may impact the contributions by the group towards provident fund, gratuity and ESIC. The Code has been published in the Gazette of India however, the effective date has not yet been notified. The Group will assess the impact of the Code when it comes into effect and will record any related impact in the period the Code becomes effective, if any.
- The outbreak of Coronavirus (COVID-19) pandemic globally and in India is causing significant disturbance and slowdown of economic activity. The management has considered the possible effects, if any, that may result from the pandemic relating to COVID-19 on all the carrying amounts of trade receivables and other current assets. In developing the assumptions and estimates relating to the uncertainties as at the Balance Sheet date in relation to the recoverable amounts of these assets, the Management has considered the country specific economic conditions prevailing as at the date of approval of these consolidated financial statements and has used internal and external sources of information to the extent determined by it.

The Group is providing healthcare services, being "essential services" there has been no suspension of operation and the Group has further taken steps for smooth functioning of its operations during the pandemic relating to COVID-19. The management has also evaluated impact of this pandemic on its business operations and based on its review and current indicators of future economic conditions, no material adjustment is required in the consolidated financial statements. Due to the temporary travel restrictions of overseas patients, business operations of the Group are expected to be lower in the coming year, though the same is not likely to have a continuing impact on the business of the Group. Further, the Management believes that there may not be material impact of COVID-19 pandemic on the financial position and performance of the Group, in the long-term. However, the impact assessment of COVID-19 is a continuing process given the uncertainties associated with its nature and duration and accordingly the impact may be different from that estimated as at the date of approval of these consolidated financial statements. The Group will continue to monitor any material changes to future economic conditions.

7. Segment Reporting at Consolidated levelBusiness segment

The Group's operation predominantly comprise of only one business segment- Income from Healthcare Services.

Geographical information

Geographical information analyses the Group's revenue by the Group's country of domicile (i.e. India) and other countries. In presenting the geographical information, segment revenue has been based on the geographical location of the customers.

(₹ in Lacs)

Region	Revenue from Operations				
	Quarter ended			Year ended	
	31-Mar-21	31-Dec-20	31-Mar-20	31-Mar-21	31-Mar-20
India	10,255.86	9,808.76	9,274.86	34,685.64	36,773.57
Outside India	2,660.03	2,609.93	4,572.23	6,154.70	19,728.22
Total	12,915.89	12,418.69	13,847.09	40,840.34	56,501.79

Region	Carrying amount of Non-Current Assets				
	Quarter ended			Year ended	
	31-Mar-21	31-Dec-20	31-Mar-20	31-Mar-21	31-Mar-20
India	48,783.32	47,867.75	46,620.79	48,783.32	46,620.79
Outside India	-	-	-	-	-
Total	48,783.32	47,867.75	46,620.79	48,783.32	46,620.79

8. Exceptional item consist of reversal of old disputed liability of Rs. 323.29 lacs carried forward from Artemis Global Life Sciences Limited (AGLSL) (the erstwhile ultimate parent company of Artemis Medicare Services Limited) prior to the merger which was under Arbitration. The Management has been advised by an independent legal expert that since the Arbitration proceedings are not being carried out for last many years, this amount is now no longer payable. Accordingly, the same has been written back by the Holding Company.

9. Previous period's figures have been regrouped / reclassified wherever necessary to correspond with the current period classification/disclosures.

Place : London
Dated : May 10, 2021



For and on behalf of the Board of Directors
of Artemis Medicare Services Limited

Onkar Kanwar

Onkar Kanwar
Chairman

Independent Auditors' Report on the Standalone Annual Financial Results of the Company Pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

INDEPENDENT AUDITORS' REPORT

To the Board of Directors of Artemis Medicare Services Limited

Report on the audit of the Standalone Annual Financial Results

Opinion

We have audited the accompanying standalone annual financial results of Artemis Medicare Services Limited (hereinafter referred to as the "Company") for the year ended 31st March, 2021, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone annual financial results:

- a. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- b. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the Company for the year ended 31st March, 2021.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results* section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our opinion on the standalone annual financial results.

Management's and Board of Directors' Responsibilities for the Standalone Annual Financial Results

These standalone annual financial results have been prepared on the basis of the standalone Ind AS annual financial statements.

Other offices

505, 5th Floor, Tower B, World Trade Tower
Sector 16, Noida, 201301
T: +91-120-4814400

4/18, Asaf Ali Road,
New Delhi-110002
T: +91-11-23274888/77410

B-XIX-220, Rani Jhansi Road, Gurgaon, Manesar
Ludhiana – 121001
T: +91-161-2774527 • F: +91-161-2774527



The Company's Management and the Board of Directors are responsible for the preparation and presentation of these standalone annual financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act; for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone annual financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion whether the company has adequate internal financial controls with reference to standalone Ind AS financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the standalone annual financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone annual financial results, including the disclosures, and whether the standalone annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.



Materiality is the magnitude of misstatement in the standalone annual financial results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the standalone annual financial results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatement in the standalone annual financial results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.


We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The standalone annual financial results include the results for the quarter ended 31st March, 2021 being the balancing figure between the audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us. (Refer Note 3)

Our opinion is not modified in respect of this matter.

For SCV & Co. LLP
CHARTERED ACCOUNTANTS
FIRM REGISTRATION No. 000235N/N500089



(RAJIV PURI)
PARTNER
MEMBERSHIP No. 084318
UDIN : 21084318AAAABI1693

PLACE: NEW DELHI
DATED: 10th MAY, 2021

ARTEMIS MEDICARE SERVICES LIMITED

Plot No.14, Sector 20, Dwarka, South West Delhi, Delhi- 110075

Ph.: +91-124-4511111; Fax: +91-124-4588899; Email: info@artemishospitals.com; Website: www.artemishospitals.com

CIN: L85110DL2004PLC126414

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2021

(₹ in Lacs)

S No.	Particulars	Quarter ended			Year ended	
		31-Mar-21	31-Dec-20	31-Mar-20	31-Mar-21	31-Mar-20
		(Audited) (Refer Note 3)	(Unaudited)	(Audited) (Refer Note 3)	(Audited)	(Audited)
1.	Income					
	(a) Revenue from Operations	12,723.39	12,227.01	13,735.54	40,206.37	56,309.09
	(b) Other Income	139.75	68.58	205.47	354.56	456.95
	Total Income	12,863.14	12,295.59	13,941.01	40,560.93	56,766.04
2.	Expenses					
	(a) Purchases of Pharmacy drugs & Medical consumables	3,542.25	3,656.59	3,656.90	11,317.43	14,035.65
	(b) Purchases of Stock in Trade	6.63	-	35.37	29.71	149.00
	(c) Changes in Inventories of Pharmacy drugs, Medical consumables & Stock in Trade	17.95	(101.59)	(282.27)	140.93	(361.67)
	(d) Employee Benefits Expense	2,144.22	2,149.89	2,606.88	8,248.65	10,239.59
	(e) Finance Costs	238.58	290.90	283.52	1,226.89	1,250.92
	(f) Depreciation and Amortization Expense	484.32	510.35	559.48	2,065.22	2,233.09
	(g) Other Expenses	5,012.71	4,915.63	6,414.32	16,964.80	26,022.92
	Total Expenses	11,446.66	11,421.77	13,274.20	39,993.63	53,569.50
3.	Profit before exceptional items and tax (1-2)	1,416.48	873.82	666.81	567.30	3,196.54
4.	Exceptional Items (Refer Note 6)	323.29	-	-	323.29	-
5.	Profit before tax (3+4)	1,739.77	873.82	666.81	890.59	3,196.54
6.	Tax Expense:					
	(a) Current Tax	670.51	-	281.70	670.51	1,139.63
	(b) Earlier Year Tax	94.14	-	(14.16)	94.14	(395.73)
	(c) Deferred Tax Charge / (Credit)	(303.72)	324.42	(49.03)	(582.77)	409.81
	Total Tax Expense	460.93	324.42	218.51	181.88	1,153.71
7.	Profit after tax for the period (5-6)	1,278.84	549.40	448.30	708.71	2,042.83
8.	Other Comprehensive Income					
	Items that will not be reclassified to profit or loss					
	(a) Remeasurement of defined employee benefit plans	17.02	(2.78)	(26.27)	8.70	(49.46)
	(b) Deferred Tax adjustment on revaluation	10.16	10.17	7.63	40.66	30.50
	(c) Income Tax relating to items that will not be reclassified to profit or loss	(5.95)	0.97	9.18	(3.04)	17.28
	Net other comprehensive income not to be reclassified to profit or loss in subsequent periods:	21.23	8.36	(9.46)	46.32	(1.68)
9.	Total comprehensive income for the period (7+8)	1,300.07	557.76	438.84	755.03	2,041.15
10.	Paid up Equity Share Capital (Face value Rs. 10/- each)	1,323.77	1,323.77	1,323.77	1,323.77	1,323.77
11.	Other Equity Excluding Revaluation Reserves	-	-	-	24,199.27	23,484.90
12.	Earning per Equity Share (Face value Rs. 10/- each)					
	(a) Basic	9.66*	4.15*	3.39*	5.35	15.43
	(b) Diluted	9.66*	4.15*	3.39*	5.35	15.43

* Not annualised



Onkar Kaumar

Notes:-

1. The above standalone audited financial results for the quarter and year ended March 31, 2021 have been reviewed by the Audit Committee and subsequently approved by the Board of Directors of the Company at their respective meetings held on May 10, 2021. The statutory auditors have expressed unmodified opinion on the aforesaid results.
2. The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015, as amended (Ind AS), as prescribed under Section 133 of the Companies Act 2013, and the other recognised accounting practices and policies to the extent applicable.
3. The results for the quarter ended March 31, 2021 and March 31, 2020, are the balancing figures between audited figures in respect of full financial year ended March 31, 2021 and March 31, 2020 respectively and published and unaudited respectively year to date figures up to the third quarter of the respective financial year then ended.
4. The Parliament of India has approved the Code of Social Security, 2020 (the Code) which may impact the contributions by the company towards provident fund, gratuity and ESIC. The Code has been published in the Gazette of India however, the effective date has not yet been notified. The Company will assess the impact of the Code when it comes into effect and will record any related impact in the period the Code becomes effective, if any.
5. The outbreak of Coronavirus (COVID-19) pandemic globally and in India is causing significant disturbance and slowdown of economic activity. The management has considered the possible effects, if any, that may result from the pandemic relating to COVID-19 on all the carrying amounts of trade receivables and other current assets. In developing the assumptions and estimates relating to the uncertainties as at the Balance Sheet date in relation to the recoverable amounts of these assets, the Management has considered the country specific economic conditions prevailing as at the date of approval of these financial statements and has used internal and external sources of information to the extent determined by it.
The Company is providing healthcare services, being "essential services" there has been no suspension of operation and the Company has further taken steps for smooth functioning of its operations during the pandemic relating to COVID-19. The management has also evaluated impact of this pandemic on its business operations and based on its review and current indicators of future economic conditions, no material adjustment is required in the financial statements. Due to the temporary travel restrictions of overseas patients, business operations of the Company are expected to be lower in the coming year, though the same is not likely to have a continuing impact on the business of the Company. Further, the Management believes that there may not be material impact of COVID-19 pandemic on the financial position and performance of the Company, in the long-term. However, the impact assessment of COVID-19 is a continuing process given the uncertainties associated with its nature and duration and accordingly the impact may be different from that estimated as at the date of approval of these financial statements. The Company will continue to monitor any material changes to future economic conditions.
6. Exceptional item consist of reversal of old disputed liability of Rs. 323.29 lacs carried forward from Artemis Global Life Sciences Limited (AGLSL) (the erstwhile ultimate parent company of Artemis Medicare Services Limited) prior to the merger which was under Arbitration. The Management has been advised by an independent legal expert that since the Arbitration proceedings are not being carried out for last many years, this amount is now no longer payable. Accordingly, the same has been written back by the Company.
7. In accordance with Ind AS 108 "Operating Segments", segment information has been given in the consolidated financial results, and therefore, no separate disclosure on segment information is given in these Standalone financial results.
8. Previous period's figures have been regrouped / reclassified wherever necessary to correspond with the current period classification/disclosures.

Place : London
Dated : May 10, 2021



For and on behalf of the Board of Directors
of Artemis Medicare Services Limited

Onkar Kanwar

Onkar Kanwar
Chairman

Artemis Medicare Services Limited
Consolidated Statement of Assets & Liabilities as at 31st March,2021

(₹ in Lacs)

Particulars	As At 31st March 2021 (Audited)	As At 31st March 2020 (Audited)
Assets		
Non-current assets		
Property, plant and equipment	32,160.51	33,379.58
Right-of-use assets	1,718.06	1,438.59
Capital work-in-progress	8,105.79	5,569.03
Goodwill	4,162.07	4,162.07
Other Intangible assets	268.70	345.48
Financial assets		
i. Loans	259.95	243.34
ii. Other financial assets	18.67	29.05
Non-current tax assets (Net)	1,675.42	1,011.26
Other non-current assets	692.77	714.78
Total non-current assets	49,061.94	46,893.18
Current assets		
Inventories	962.42	1,075.34
Financial assets		
i. Trade receivables	5,471.70	7,659.75
ii. Cash and cash equivalents	1,916.20	1,160.82
iii. Bank balances other than (ii) above	1,195.78	404.44
iv. Loans	54.20	111.24
v. Other financial assets	463.22	360.34
Other current assets	883.47	979.21
Total current assets	10,946.99	11,751.14
Total Assets	60,008.93	58,644.32
Equity and liabilities		
Equity		
Equity share capital	1,323.77	1,323.77
Other equity	30,695.62	30,000.29
Equity attributable to shareholders of the Company	32,019.39	31,324.06
Non-controlling Interests	154.99	47.34
Total equity	32,174.38	31,371.40
Liabilities		
Non-current liabilities		
Financial liabilities		
i. Borrowings	10,773.34	6,557.85
ii. Lease Liabilities	1,612.99	1,395.06
Provisions	664.96	631.41
Deferred tax liabilities (Net)	2,901.46	2,908.37
Total non-current liabilities	15,952.75	11,492.69
Current liabilities		
Financial liabilities		
i. Borrowings	-	1,088.63
ii. Lease Liabilities	318.38	136.84
iii. Trade payables		
(A) Total Outstanding dues of Micro Enterprises and Small Enterprises	1,099.10	995.49
(B) Total Outstanding dues of Creditors other than Micro Enterprises and Small Enterprises	4,627.84	6,465.77
iv. Other financial liabilities	2,946.67	4,294.04
Other current liabilities	1,870.53	1,879.34
Provisions	1,019.28	920.12
Total current liabilities	11,881.80	15,780.23
Total liabilities	27,834.55	27,272.92
Total equity and liabilities	60,008.93	58,644.32



Artemis Medicare

Artemis Medicare Services Limited
Consolidated Cash Flow Statement for the year ended 31st March, 2021

Particulars	(₹ in Lacs)	
	Year ended 31st March 2021 (Audited)	Year ended 31st March 2020 (Audited)
Cash flow from operating activities		
Profit/(Loss) before tax	753.02	3,062.91
Adjustments for:		
Depreciation and amortization expense	2,151.38	2,263.05
Interest Income	(182.37)	(50.06)
Finance Cost	1,084.55	1,053.47
Exceptional Items	(323.29)	-
Unclaimed Credit balances / provisions no longer required written back	(85.48)	(61.42)
Allowance for Expected Credit Loss	307.63	286.95
Unrealised foreign exchange gain (net)	26.07	(64.12)
Loss / (Gain) on Sale / Scrap of Property, Plant and Equipment (Net)	23.81	13.56
Operating cash flow before working capital changes	3,755.32	6,504.34
Adjustments for Changes in Working Capital		
- (Increase)/ Decrease in trade receivables	1,854.35	(21.26)
- (Increase)/ Decrease in inventories	112.92	(381.64)
- (Increase)/ Decrease in Loan (Current)	57.04	86.00
- (Increase)/ Decrease in Loan (Non -Current)	(16.61)	12.52
- (Increase)/ Decrease in other financial assets (Current)	(102.88)	154.36
- (Increase)/ Decrease in other financial assets (Non - Current)	10.38	3.37
- (Increase)/ Decrease in other Current Assets	95.74	(231.40)
- (Increase)/ Decrease in Other Non Current Assets	(1,620.47)	(1,164.60)
- Increase/(Decrease) in trade payables	(1,648.85)	153.02
- Increase/(Decrease) in Provisions (Current)	99.16	64.26
- Increase/(Decrease) in Provisions (Non - Current)	43.17	84.99
- Increase / (Decrease) in Other current liabilities (Current)	(8.81)	(133.90)
- Increase / (Decrease) in Other financial liabilities (Current)	(118.08)	903.24
Cash generated from operations	2,512.38	6,033.30
Income tax refund / (paid)	213.68	(425.11)
Net cash generated from operating activities	2,726.06	5,608.19
Cash flow from investing activity		
Purchase of Property, Plant & Equipment / CWIP	(3,450.12)	(2,600.32)
Proceeds from sale of Property, Plant & Equipment	316.77	11.14
Maturity / (investments) of / in fixed deposits having original maturity of more than 3 months	(791.34)	(90.05)
Interest received	182.37	50.06
Net cash (used in) investing activities	(3,742.32)	(2,629.17)
Cash flow from financing activity		
Proceeds from non current borrowings	5,478.77	3,395.85
Repayment of non current borrowings	(1,431.42)	(2,336.02)
Repayment of current borrowings (net)	(1,088.63)	(2,698.96)
Proceeds from issuance of shares to non controlling interests	140.00	87.50
Payment of lease liabilities	(242.53)	(136.98)
Interest paid	(1,084.55)	(1,053.47)
Net cash generated from financing activities	1,771.64	(2,742.08)
Net increase in cash & cash equivalents	755.38	236.94
Cash & cash equivalents as the beginning of the year	1,160.82	923.88
Cash & cash equivalents as the end of the year	1,916.20	1,160.82
Components of cash and cash equivalents		
Cash on hand	135.60	80.15
Balances with Banks:		
On current accounts	1,180.60	1,080.67
Fixed Deposit in banks having original maturity of 3 months or less	600.00	-
On deposit accounts	1,195.78	404.44
Less: Fixed deposits not considered as cash equivalents	(1,195.78)	(404.44)
Total Cash and Cash Equivalents	1,916.20	1,160.82



Online Kaunap

Artemis Medicare Services Limited
Standalone Statement of Assets & Liabilities as at 31st March, 2021

(₹ in Lacs)

Particulars	As At 31st March 2021 (Audited)	As At 31st March 2020 (Audited)
Assets		
Non-current assets		
Property, plant and equipment	31,033.10	32,766.98
Right-of-use assets	1,718.06	1,438.59
Capital work-in-progress	8,100.53	5,569.03
Goodwill	4,162.07	4,162.07
Other Intangible assets	268.70	345.48
Financial assets		
i. Investments	429.00	169.00
ii. Loans	259.95	243.34
iii. Other financial assets	18.67	29.05
Non-current tax assets (Net)	1,643.43	1,003.04
Other non-current assets	691.82	714.70
Total non-current assets	48,325.33	46,441.28
Current assets		
Inventories	926.66	1,053.32
Financial assets		
i. Trade receivables	5,297.34	7,650.71
ii. Cash and cash equivalents	1,688.85	1,119.50
iii. Bank balances other than (ii) above	1,195.78	404.44
iv. Loans	53.45	110.47
v. Other financial assets	529.10	359.26
Other current assets	879.05	977.44
Total current assets	10,570.23	11,675.14
Total Assets	58,895.56	58,116.42
Equity and liabilities		
Equity		
Equity share capital	1,323.77	1,323.77
Other equity	30,838.24	30,083.21
Total equity	32,162.01	31,406.98
Liabilities		
Non-current liabilities		
Financial liabilities		
i. Borrowings	9,877.04	6,057.19
ii. Lease Liabilities	1,612.99	1,395.06
Provisions	658.06	626.87
Deferred tax liabilities (Net)	2,982.88	2,945.18
Total non-current liabilities	15,130.97	11,024.30
Current liabilities		
Financial liabilities		
i. Borrowings	-	1,088.63
ii. Lease Liabilities	318.38	136.84
iii. Trade payables		
(A) Total Outstanding dues of Micro Enterprises and Small Enterprises	1,099.10	995.49
(B) Total Outstanding dues of Creditors other than Micro Enterprises and Small Enterprises	4,486.71	6,407.71
iv. Other financial liabilities	2,820.91	4,264.99
Other current liabilities	1,859.58	1,871.66
Provisions	1,017.90	919.82
Total current liabilities	11,602.58	15,685.14
Total liabilities	26,733.55	26,709.44
Total equity and liabilities	58,895.56	58,116.42



Anurag Kaumar

Artemis Medicare Services Limited
Standalone Cash Flow Statement for the year ended 31st March 2021

Particulars	(₹ in Lacs)	
	Year ended 31st March 2021 (Audited)	Year ended 31st March 2020 (Audited)
Cash flow from operating activities		
Profit before tax	890.59	3,196.54
Adjustments for:		
Depreciation and amortization expense	2,065.22	2,233.09
Interest Income	(183.37)	(45.99)
Finance Cost	1,019.52	1,024.19
Exceptional Items	(323.29)	-
Unclaimed Credit balances / provisions no longer required written back	(85.48)	(61.42)
Allowance for Expected Credit Loss	307.63	286.95
Unrealised foreign exchange gain (net)	26.07	(64.12)
Loss / (Gain) on Sale / Scrap of Property, Plant and Equipment (Net)	19.24	11.47
Operating cash flow before working capital changes	3,736.13	6,580.71
Adjustments for Changes in Working Capital		
- (Increase)/ Decrease in trade receivables	2,019.66	(12.22)
- (Increase)/ Decrease in inventories	126.67	(359.62)
- (Increase)/ Decrease in Loan (Current)	57.02	86.77
- (Increase)/ Decrease in Loan (Non -Current)	(16.62)	12.52
- (Increase)/ Decrease in other financial assets (Current)	(169.84)	155.45
- (Increase)/ Decrease in other financial assets (Non - Current)	10.38	3.37
- (Increase)/ Decrease in other Current Assets	98.40	(214.92)
- (Increase)/ Decrease in Other Non Current Assets	(961.51)	(1,164.28)
- Increase/(Decrease) in trade payables	(1,731.91)	97.50
- Increase/(Decrease) in Provisions (Current)	98.09	63.96
- Increase/(Decrease) in Provisions (Non - Current)	39.89	80.45
- Increase / (Decrease) in Other current liabilities (Current)	(12.08)	(140.87)
- Increase / (Decrease) in Other financial liabilities (Current)	(802.34)	876.65
Cash generated from operations	2,491.94	6,065.47
Income tax refund / (paid)	237.45	(416.89)
Net cash generated from operating activities	2,729.39	5,648.58
Cash flow from investing activity		
Purchase of Property, Plant & Equipment / CWIP	(2,826.23)	(1,956.57)
Proceeds from sale of Property, Plant & Equipment	303.69	11.14
Maturity / (investments) of / in fixed deposits having original maturity of more than 3 months	(791.34)	(90.06)
Investment made in subsidiary	(260.00)	(162.50)
Interest received	183.37	45.99
Net cash (used in) investing activities	(3,390.51)	(2,152.00)
Cash flow from financing activity		
Proceeds from non current borrowings	5,012.57	2,850.85
Repayment of non current borrowings	(1,431.42)	(2,291.68)
Repayment of current borrowings (net)	(1,088.63)	(2,698.96)
Payment of lease liabilities	(242.53)	(136.98)
Interest paid	(1,019.52)	(1,024.19)
Net cash generated from financing activities	1,230.47	(3,300.96)
Net increase in cash & cash equivalents	569.35	195.62
Cash & cash equivalents as the beginning of the year	1,119.50	923.88
Cash & cash equivalents as the end of the year	1,688.85	1,119.50
Components of cash and cash equivalents		
Cash on hand	135.14	79.69
Balances with Banks:		
On current accounts	953.71	1,039.81
Fixed Deposit in banks having original maturity of 3 months or less	600.00	-
On deposit accounts	1,195.78	404.44
Less: Fixed deposits not considered as cash equivalents	(1,195.78)	(404.44)
Total Cash and Cash Equivalents	1,688.85	1,119.50



Omkar Kumar

ARTEMIS MEDICARE SERVICES LIMITED

Plot No.14, Sector 20, Dwarka, South West Delhi, Delhi- 110075
Ph.: +91-124-4511111; Fax: +91-124-4588899; Email: info@artemishospitals.com; Web site: www.artemishospitals.com
CIN: L85110DL2004PLC126414

EXTRACT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2021

(₹ in Lacs)

S. No.	Particulars	Quarter Ended		Year ended	
		31-Mar-21	31-Mar-20	31-Mar-21	31-Mar-20
		(Audited)			
1	Total Income from Operations	12,915.89	13,847.09	40,840.34	56,501.79
2	Net Profit for the period (before Tax, Exceptional and/or Extraordinary Items)	1,393.72	632.09	429.73	3,062.91
3	Net Profit for the period before tax (after Exceptional and/or Extraordinary Items)	1,717.01	632.09	753.02	3,062.91
4	Net Profit for the period after tax (after Exceptional and/or Extraordinary Items)	1,265.16	422.28	616.00	1,946.01
5	Total Comprehensive Income for the period [comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	1,287.05	412.82	662.98	1,944.33
6	Paid-up Equity Share Capital (Equity Shares of Rs.10/-each)	1,323.77	1,323.77	1,323.77	1,323.77
7	Reserves (excluding Revaluation Reserve)			24,056.65	23,401.98
8	Earning per Equity Share (Face value Rs.10/-each)				
	(a) Basic	9.59*	3.26*	4.90	14.95
	(b) Diluted	9.59*	3.26*	4.90	14.95
	(* Not annualised)				

Notes:

The key standalone financial information of the Company is as under:

(₹ in Lacs)

S. No.	Particulars	Quarter Ended		Year ended	
		31-Mar-21	31-Mar-20	31-Mar-21	31-Mar-20
		(Audited)			
1	Total Income from Operations	12,723.39	13,735.54	40,206.37	56,309.09
2	Net Profit for the period before Tax after Exceptional Items	1,739.77	666.81	890.59	3,196.54
3	Net Profit for the period after Tax	1,278.84	448.30	708.71	2,042.83

The above is an extract of the detailed format of audited financial results filed with the Stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the financial results (Consolidated/ Standalone) are available on the Stock Exchange websites. (National Stock Exchange of India Limited (www.nseindia.com) & BSE Limited (www.bseindia.com) and on the company's website (www.artemishospitals.com).

The above results for the quarter and year ended March 31, 2021 were reviewed by the Audit Committee meeting held on May 10, 2021 and approved by the Board of Directors meeting held on May 10, 2021. The Statutory Auditors have expressed an unmodified opinion on the aforesaid results.

The above financial results have been prepared in accordance with the companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as prescribed under Section 133 of the Companies Act 2013, and the other recognised accounting practices and policies to the extent applicable.



For and on behalf of the Board of Directors
of Artemis Medicare Services Limited

Onkar Kanwar

Onkar Kanwar
Chairman

Place : London
Dated : May 10, 2021

OUR
SPECIALITY
IS
YOU

www.artemishospitals.com

ARTEMIS[®]
HOSPITALS

ONLINE FILING

Date: 10th May 2021

The Secretary National Stock Exchange of India Ltd. Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai-400 051	The Secretary, BSE Ltd Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400 001
---	---

Sub: Declaration pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended in respect of Audit Reports with unmodified opinion for the Financial year ended 31st March, 2021.

Dear Sir/Mam,

Pursuant to Regulation 33 (3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended vide Circular No. CIR/CFD/CMD/56/2016 dated May 27, 2016, it is hereby declared that the Auditors of the Company, M/s. SCV & Co. LLP, Chartered Accountants (Firm Registration No. 000235N/N500089), have issued the Audit Reports with unmodified opinion on the Audited Financial Statements (Standalone & Consolidated) for the financial year ended 31st March, 2021.

Submitted for your information & records.

Thanking you,
Yours Faithfully,

For Artemis Medicare Services Limited

**Dr. Devlina Chakravarty
Managing Director**



◆ **Artemis Hospital (A unit of Artemis Medicare Services Ltd.)**

◆ Sector 51, Gurugram - 122001, Haryana, India. Ph.: +91-124-4511 111 | Fax: +91-124-4588 899

◆ **Emergency & Trauma: +91-124-4588 888**

Registered Office: Plot No. 14, Sector 20, Dwarka, New Delhi - 110075 | Corporate Office: Artemis Hospital, Sector 51, Gurugram - 122001, Haryana, India

CIN: L85110DL2004PLC126414 | GST: 06AAFCA0130M1Z1(HR), 07AAFCA0130M1ZZ(DEL) | TAN: DELA16048E | PAN: AAFCA0130M | Email: info@artemishospitals.com





www.artemishospitals.com



ARTEMIS MEDICARE SERVICES LIMITED

List of Directors as on 10.05.2021

Sr. No.	Name of Directors	Category	DIN
1.	Mr. Onkar Kanwar	Chairman and Non-Executive Director	00058921
2.	Ms. Shalini Kanwar Chand	Non-Executive Director	00015511
3.	Mr. Neeraj Kanwar	Non-Executive Director	00058951
4.	Dr. Nirmal Kumar Ganguly	Non-Executive Director	02316154
5.	Dr. S. Narayan	Independent Director	00094081
6.	Dr. Sanjaya Baru	Independent Director	05344208
7.	Dr. Devlina Chakravarty	Managing Director	07107875
8.	Mr. Sanjib Sen	Independent Director	08801337
9.	Ms. Deepa Gopalan Wadhwa	Independent Director	07862942
10.	Mr. Sunil Tandon	Additional Independent Director	08342585

For Artemis Medicare Services Limited

Shilpa Budhia
Company Secretary & Compliance Officer



Artemis Hospital (A unit of Artemis Medicare Services Ltd.)
Sector 51, Gurugram - 122001, Haryana, India. Ph.: +91-124-4511 111 | Fax: +91-124-4588 899
Emergency & Trauma: +91-124-4588 888

Registered Office: Plot No. 14, Sector 20, Dwarka, New Delhi - 110075 | Corporate Office: Artemis Hospital, Sector 51, Gurugram - 122001, Haryana, India
CIN: L85110DL2004PLC126414 | GST: 06AAFCA0130M121(HR), 07AAFCA0130M12Z(DEL) | TAN: DELA16048E | PAN: AAFCA0130M | Email: info@artemishospitals.com

